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Induced BDNF-Secreting Human Mesenchymal
Stem Cells: Implications for Cell-Based Therapies
in Parkinson’s Disease
Rodrigo Somoza,1 Carlos Juri,2 Mauricio Baes,3 Ursula Wyneken,3 Francisco Javier Rubio1,3It is thought that the ability of humanmesenchymal stem cells (hMSC) to deliver neurotrophic factorsmight be
potentially useful for the treatment of neurodegenerative disorders. The aim of the present studywas to char-
acterize signals and/ormolecules that regulate brain-derived neurotrophic factor (BDNF) protein expression/
delivery in hMSC cultures and evaluate the effect of epigenetically generated BDNF-secreting hMSC on the
intact and lesioned substantia nigra (SN). We tested 4 different culture media and found that the presence
of fetal bovine serum (FBS) decreased the expression of BDNF, whereas exogenous addition of epidermal
growth factor (EGF) and basic fibroblast growth factor (bFGF) to serum-free mediumwas required to induce
BDNF release (1256 12 pg/day/106 cells). These cells were called hM(N)SC. Although the inductionmedium
inhibited the expression of alpha smooth muscle actin (ASMA), an hMSC marker, and increased the nestin-
positive subpopulation of hMSC cultures, the ability to express BDNF was restricted to the nestin-negative
subpopulation. One week after transplantation into the SN, the human cells integrated into the surrounding
tissue, and some showed a dopaminergic phenotype. We also observed the activation of Trk receptors for
neurotrophic factors around the implant site, including the BDNF receptor TrkB. When we transplanted
these cells into the unilateral lesioned SN induced by striatal injection of 6-hydroxydopamine (6-OHDA),
a significant hypertrophy of nigral tyrosine hydroxylase (TH)1 cells, an increase of striatal TH-staining and sta-
bilization of amphetamine-induced motor symptoms were observed. Therefore, hMSC cultures exposed to
the described induction mediummight be highly useful as a vehicle for neurotrophic delivery to the brain and
specifically are strong candidates for future therapeutic application in Parkinson’s disease.
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Unilateral 6-hydroxydopamine lesionINTRODUCTION
Bone marrow (BM) contains mesenchymal stem
cells (MSCs), also termed multipotent stromal cells,
with the ability to differentiate in vitro into mesenchy-
mal and nonmesenchymal lineages, including neuronal
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6/j.bbmt.2010.06.006for transplantation in several neurodegenerative
diseases, but the mechanisms responsible for a
beneficial outcome are not fully understood [9]. A pos-
sible mechanism involved in the neuroprotective effect
of MSCs is neural transdifferentiation. However, it is
currently thought that the therapeutic benefits of
MSCs depend on their ability to produce soluble
factors that can promote neuronal cell survival and
neuritogenesis [10,11], stimulation of axonal growth
[12,13], functional recovery [14,15], and modulation
of microglial activation [16]. At present, the positive
behavioral effects observed after MSC transplantation
in the striatum, which is the usual target implantation
region of parkinsonian animal models, cannot be ex-
plained by the low/insufficient number of dopaminer-
gic donor neurons derived from the grafted cells
[17-19], but it may depend on immunomodulation
and/or growth factor delivery [9,11,17,20].
Parkinson’s disease (PD) is characterized by the
degeneration of nigrostriatal dopaminergic neurons
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[21] and is associated with reduced levels of neurotro-
phins such as brain-derived neurotrophic factor
(BDNF) [22-24]. Dopaminergic neurons of the SNpc
depend on BDNF [25]. BDNF is produced mainly in
nigral neurons [26], which also express its receptor
TrkB [27]. Infusion of BDNF into the SNpc region
promotes survival of axotomized nigrostriatal dopami-
nergic neurons [28]. Additionally, intranigral antisense
oligonucleotide infusion indicated that loss of BDNF
expression leads to dopaminergic neuronal death [29].
Herein, we suggest that BDNF supplemented by cells
implanted in a nigral location could be better suited
for a neurotrophin-based therapy for PD than a striatal
placement [30].
Some previous results indicate that hMSC in cul-
ture express BDNF using standard and induction con-
ditions [10,11,20,31-34], but other reports observed
that significant BDNF release is obtained only after
BDNF gene transfer into hMSC [13,35-37]. To date,
the variability of results published with regard to the
levels and types of neurotrophins produced by hMSC
could be explained by the age of the human donors or
the method used to isolated hMSC from BM [38]. In
addition, the presence of fetal bovine serum (FBS) in
the medium is the most variable factor contributing
to heterogeneous results because of its composition
and endogenous levels of growth factors and cytokines,
which can vary based on the batch and quantity used
[39]. These factors could mildly modify the biology
of the hMSC (eg, the proteins they express and/or se-
crete). We previously observed BDNF in conditioned
media obtained from hMSC cultures isolated by plastic
adhesion after exposure to a defined serum-free me-
dium [34]. In the present study, we evaluated the effects
of FBS supplemented with both epidermal growth fac-
tor (EGF) and basic fibroblast growth factor (bFGF) on
gene expression, cell proliferation, and the ability to
express and/or release BDNF. We also evaluated the
in vivo effect of BDNF-secreting hMSC, called
hM(N)SC, in the intact and lesioned rat SNpc. Induced
human cells integrated perfectly into the rat SN, some
of which differentiated into a dopaminergic phenotype
and activated Trk receptors at the implant site. Our
data suggest that epigenetically generated hM(N)SC
exert neurotrophic effect on the impaired dopaminer-
gic nigrostriatal system.MATERIALS AND METHODS
Isolation and Expansion of hMSC Cultures
hMSC cultures were isolated by plastic adhesion
and characterized after 1 passage as described previ-
ously [34]. After informed consent, BM aspirates were
collected from 5 normal young individuals undergoing
BM harvest for allogeneic transplantation, as part ofa protocol approved by the Ethical Committee of the
Hematology Department of Clinica Alemana (San-
tiago, Chile). Total cells were seeded at a density of
1 106 nucleated cells/cm2 in a-minimal essential me-
dium supplemented with 10% FBS and 0.8 mg/L gen-
tamycin (MSC-medium). After 24 hours, nonadherent
cells were removed by replacing the culture medium.
When the foci of fibroblast-like cells were confluent,
the cells were detached with 0.25% (p/v) trypsin and
2.65 mM EDTA and subcultured at 7  103 cells/cm2
for further expansion. Isolated cells were characterized
by real-time RT-PCR for CD34, CD105, and alpha
smoothmuscle actin (ASMA), and their capacity to dif-
ferentiate in vitro into adipocytes, chondrocytes, and
osteocytes was evaluated as described previously [34].
Culture Media Composition
To evaluate the effect of FBS and specific growth
factors (EGF and bFGF), we cultured cells in MSC-
medium, MSC 1 GF-medium (MSC-medium with
human EGF plus human bFGF, both at 10 ng/mL
[R&D Systems, Minneapolis, MN]), NSC-medium
(DMEM/F12 [1:1] [Gibco, Grand Island, NY], 1%
bovine serum albumin [BSA, Merck, Rahway, NJ],
6 g/LD[1]-glucose [Merck], 0.8mg/Lgentamicin sup-
plemented with N2 and B27 supplements [Gibco]) and
NSC 1 GF-medium (NSC-medium supplemented
withEGFandbFGF, 10ng/ml of each) for 3 and8days.
Cellular Viability and Proliferation
To examine cell viability and proliferation, we used
a colorimetric assay using WST-1 reagent (Roche,
Germany), a tetrazolium salt that is converted into
formazan dye by mitochondrial dehydrogenases. Cells
were seeded at a density of 4  103 cells/cm2, and 2 to
4 hours later, WST-1 was diluted 1/10 (v/v) in the
respective serum-free media and incubated for 4 hours
at 37C.The net absorbance at 450 nmwas normalized
with respect to day 0.
RT-PCR Analysis
Total RNA was isolated from cells using
TRIZOL reagent (Invitrogen, Carlsbad, CA) accord-
ing to themanufacturer’s instructions, and 1 mg of total
RNA was used for reverse transcription (RT). PCR
was performed in a capillary containing 100 ng of
cDNA, PCR LightCycler-DNA Master SYBR Green
reaction mix (Roche, Indianapolis, IN), 3-4 mM
MgCl2, and 0.5 mM of each specific primer, using
a LightCycler thermocycler (Roche). For primer
sequences and control human cell lines, see the
description from a previous article [34]. Negative con-
trols without reverse transcriptase were performed.
Negative PCR results were validated by amplification
of the housekeeping gene GAPDH. PCR sensitivity
for each neural gene was calculated previously [34].
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hMSC were seeded in MSC-medium at a density
of 7  103 cells/cm2. Cells were allowed to attach to
the dish for 2 to 4 hours, and then the MSC-medium
was replaced with the 4 corresponding types of media.
After 48 hours, the media were collected and filtered
using 0.2-mmpore filters (Orange Scientific, Belgium).
BDNF Quantification
Samples were assessed for BDNF concentrations
using the BDNF Emax ImmunoAssay System Kit
(Promega, Madison, WI) according to the manufac-
turer’s protocol. A standard curve of recombinant
human BDNF ranging from 7.8 to 500 pg/mL was de-
termined for each titer plate. The absorbance values
were expressed as pg of BDNF produced by a million
cells in 24 hours. BDNF standards and experimental
samples were performed in triplicate, and the BDNF
concentration was calculated from absorbance values
at 450 nm, minus the absorbance of the corresponding
cell-free culture media.
Immunodetection
We used different antibodies to detect cell-specific
proteins. Nestin was detected in cells by both immuno-
fluorescence and flow cytometry with a mouse mono-
clonal antibody (mAb; 1:100, R&D System); BDNF
protein in cell cultures was detected with a rabbit poly-
clonal antibody (pAb) (1:1000. Santa Cruz Biotechnol-
ogy, Santa Cruz, CA); grafted hM(N)SC in brain
sections was detected using a mouse mAb against
hRNP (1:100, Chemicon, Temecula, CA); dopaminer-
gic neuronswere detectedwith an anti-THmousemAb
antibody (1:1000, Sigma, St. Louis, MO) for immuno-
histochemistry or anti-TH rabbit pAb antibody
(1:5000, Chemicon) for immunofluorescence; and
high-affinity BDNF receptor and phospho-Trk recep-
tors were detected in brain sections using rabbit pAb
TrkB (1:800, BD Transduction Laboratories, San
Jose, CA) and mouse mAb phospho-TrkA (Tyr490)
(1:400, Cell Signaling, Danvers, MA), respectively.
The rabbit antibody against phospho-Tyr-816 of
TrkB was kindly provided by Moses Chao and used
at a 1:100 dilution. For immunohistochemistry, pri-
mary antibodies were detected with biotinylated
antimouse secondary antibody (Vector Laboratories,
Burlingame, CA) and 3,3-diaminobenzidine tetrahy-
drochloride (DAB) using a nickel-intensified reaction
according to the published protocol [40]. Immunofluo-
rescence for nestin was done using a goat antimouse
PE-conjugated secondary antibody (1:100, BD Biosci-
ences, Mountain View, CA). Double immunostaining
for nestin/BDNF, hRNP/TH and TrkB/pTrkA was
carried out with specie-specific secondary antibodies
coupled to Alexa Fluor488 and Alexa Fluor555
(1:200, Invitrogen, Eugene, OR).Flow Cytometry
A total of 1  106 cells were fixed in 70% ethanol.
Cell fractions of 2  105 cells were resuspended in
PBS containing 2% FBS and first incubated with
primary antibody for 60 minutes at 4C, washed twice,
and then incubated with PE-conjugated secondary
antibody for 60 minutes at 4C (for antibody specifica-
tions see the Immunodetection section). Cell fluores-
cence was evaluated by flow cytometry using
FACScan (BDBiosciences), and the datawere analyzed
using CellQuest software (BD).
Cell Nigral Transplantation
and 6-Hydroxydopamine Injection
Surgical procedures were performed under the
supervision of the Animal Care Committee at the
Universidad del Desarrollo, Chile. Care of animals
and protocols were in accordance with institutional
guidelines. Male Sprague Dawley rats (Universidad
de Chile, Santiago, Chile), weighing 220-280 g, were
anesthetized with a mix of ketamine (50 mg/kg) and
xilacine (10 mg/kg). Using a stereotactic frame and
a 10-mLHamilton syringe we used the following coor-
dinates from rat brain atlas [41]. For nigral transplanta-
tion we injected 4 mL of phosphate buffer solution
(pH 7.4) containing 5% of heterologous rat serum
(vehicle) or hM(N)SC (5  104 cells/mL) at 2 depths
ventral to the SNpc (from bregma, AP, anteroposte-
rior; ML, mediolateral; V, vertical from dura). AP
25.0 mm, ML 21.6 mm, V 28.4, and 28.2 mm,
tooth-bar 5 23.3. For the experiment in lesioned
SN, 1 week before cell transplantation were injected
with 6 mL of 6-OHDA (4 mg/mL) in 0.02% (1)-sodium
L-ascorbate (Sigma) of saline solution distributed in
3 sites into the right dorsal Str: AP 21.0 mm, ML
23.5 mm, V25.0,24.5, and24.0mm, tooth-bar5 0.
Animals were immunosuppressed by daily injections of
dexamethasone (initial dose of 0.5 mg/kg subcutane-
ously), starting 1 day before transplantation, until the
end of the experiment (1 week for intact animals and
3 weeks for lesioned animals).
Histology
Brains were fixed in 4% paraformaldehyde in 0.1
M phosphate buffer, pH 7.4, and processed as de-
scribed previously [40]. Serial coronal sections of 30
mm or 40 mm were collected for immunofluorescence
or immunochemistry assays, respectively. Brain slices
were visualized under a light microscope (AxiosKop,
Zeiss, Germany) or a fluorescence confocal micro-
scope (Olympus Fluoview FW1000).
Estimates of Sprouting
and Motor Function Assessment
For this aim, we use a relative index of extent of
fiber innervation based on the validity of densitometric
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TheTH-staining area wasmeasured based on segmen-
tation on the basis of gray level of the stained region and
the background pixels from brain section images using
NIH Scion Image software. To selectively detect TH
immunoreactivity the thresholding lower and upper
gray values were set at 152 and 252, respectively.The
sprouting index was calculated by dividing the immu-
nopositive area in the Str by the number of TH1 cells
in the SNpc. Rotational motor response was analyzed
in both lesioned groups (lesioned-sham and lesioned-
grafted) with methamphetamine hydrochloride (5 mg/
kg/dose intraperitoneally (i.p.), Cidrin, Abbott Labo-
ratories, Chile) at 1 week after the 6-OHDA intrastria-
tal injection and 3 weeks after vehicle or hM(N)SC
intranigral injection. The rotational behaviors (360 de-
gree turns) were assessed for 30 minutes with a video
camera and the analyses were based on the net scores
(ipsilateral minus contralateral rotations).Figure 1. Characterization of hMSC cultures in four different culture
media. (A) Representative images taken to evaluate cell morphology
and the number of cells after 8 days in culture. Scale bars: 100 mm. (B)
Proliferation curve based on absorbance measurements (450 nm) from
the WST-1 test. All four groups were different from each other at day
3 (#, P \ .05). The serum-containing media (MSC and MSC 1 GF)
were able to expand cells from hMSC cultures until at least day 8. The
serum-free media (NSC and NSC1GF) arrested cell proliferation after
the third day, being more pronounced in the absence of exogenous
growth factors (NSC-medium) at days 3 and 8 (*P\.05). The data areQuantifications
For SN analysis, cell counts and soma area were
obtained from a total of 5-10 sections analyzed per
animal, restricted to interaural 4.20 mm/bregma
24.80mmand interaural 2.96mm/bregma26.04mm.
Data from soma area was restricted to cells.124 mm2.
Statistical significance for comparing hemispheres was
determined using the nonparametric Mann-Whitney
test. For Str analysis, striatal area were analyzed from
5 to 10 sections per animal restricted to interaural
10.00 mm/bregma 1.00 mm and interaural 8.20 mm/
bregma 20.80 mm [43]. A nonparametric Mann-
Whitney test was used for AIR test analysis. Statistical
analysis were done using the Software SPSS15 (SPS,
Chicago, Inc.), and all data were processed using the
standard error mean (SEM).the mean6 SEM of absorbance values obtained from four independent
cultures measured.RESULTS
Effect of Different CultureMedia on the Biologic
Properties of hMSC Cultures
We tested 4 differentmedia to obtain a protocol that
should allow the generation of BDNF-secreting cells
from hMSC cultures: serum-containing medium that
has been used to isolate hMSC from BM [34,44]
(MSC-medium), serum-free medium that has been
used to isolate neural stem cells from the olfactory bulb
[34,45] (NSC-medium), and their corresponding
media supplemented with exogenous EGF and bFGF
(Growth Factors,GF;MSC1GF-medium andNSC1
GF-medium).
Cells grown in the serum-containing media (MSC
and MSC 1 GF) had similar fibroblast-like morphol-
ogies, whereas cells in the serum-free media (NSC
and NSC 1 GF) were mostly enlarged and flattenedby day 8 (Figure 1A). Doubling times at day 3 ranged
from 24 to 72 hours in the following sequence: MSC1
GF-medium\MSC-medium\NSC1GF-medium
\NSC-medium (Figure 1B). From 3 to 8 days, both
MSC-type serum-containing media yielded vigorously
proliferating cultures compared to NSC-type serum-
free media. As shown, hMSC proliferation in serum-
free media decreased quickly between the third
and the eighth day, regardless of the presence of
GF. However, cell viability only decreased at day 8
when cultures were grown in the absence of both FBS
and exogenous GF (NSC-medium: 3 days, 1.78 6
0.20; 8 days, 0.636 0.10; P5 .05; Figure 1B). We ob-
served a multineural gene expression pattern in
undifferentiated culture conditions (MSC-medium;
real-time RT-PCR data, Table 1), as described previ-
ously [34]. The addition of EGF and bFGF to the
Table 1. Effect of Media on the Gene Expression Profile* of
hMSC Cultures† at Days 3 and 8
Medium Day ASMA Nestin NF-M GFAP GalC GAPDH
MSC 3 + + + +3 +3 +
8 + + + + + +
MSC + GF 3 + + + + +3 +
8 +3 +3 +3 +3 +3 +
NSC 3 +2 +2 + +2 +3 +
8 2 2 + +1 +2 +
NSC + GF 3 2 +3 + +2 +2 +
8 2 +2 + +1 +3 +
ASMA indicates alpha-smoothmuscle actin; NF-M,medium chain neuro-
filament; GFAP, glial fibrillary acidic protein; GalC, galactocerebroside;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase as a housekeeping
gene; MSC, mesenchymal stem cells.
+, detected;2, nondetected; numbers in superscript indicates the num-
ber of positive samples; absence of superscript numbers indicate 4 of 4
positive or negative results.
*Mesenchymal marker (ASMA) and neural markers (Nestin, NF-M,
GFAP, GalC).
†From 4 different donors analyzed by RT-PCR in four different types of
media.
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rate but did not change their fibroblast morphology
and gene expression pattern. In contrast, serum-free
media affected the gene expression pattern andFigure 2. The application of NSC1 GF-medium induces BDNF secretion in
Flow cytometry data from a representative hMSC culture indicate that the p
growth factors (MSC 1 GF and NSC 1 GF) between the third (3) and eig
releasing hMSC. BDNF levels were measured by ELISA using supernatant ob
(C-D) Immunofluorescence images show immunolabeling with anti-nestin (re
cultures after 3 days in culture with MSC-medium (hMSC) or NSC 1 GF-me
suggested by the absence of colocalization of both proteins. Cell nuclei weremorphology of hMSC (Table 1 and Figure 1A). Al-
though neuronal and glial genes such as NF-M,
GFAP, and GalC were expressed in all conditions
(Table 1), the expression of the mesenchymal marker
ASMA was undetectable by RT-PCR, and the nestin
gene was only expressed in cells cultured in NSC 1
GF-medium. We then quantified nestin1 cells by flow
cytometry from cultures exposed to MSC-medium
(hMSC) or NSC 1 GF-medium (hM(N)SC). The
nestin1 cell subpopulation remained stable throughout
the time of the experiment (from day 3 until day 8) only
when cultured inmedia supplemented with growth fac-
tors (Figure 2A). Moreover, the NSC 1 GF-medium
induced nearly a 2-fold increase in the percentage of
nestin1 cells after 3 days (flow cytometry data: MSC-
medium, 26.9 6 6.1%, n 5 4; NSC 1 GF-medium,
50.5%6 3.5%, n5 3; P5 .0286). In addition, we eval-
uated the effect of the 4 types of media on the synthesis
and secretion of BDNF. In the supernatant of hMSC
cultures exposed to NSC 1 GF-medium, we detected
a BDNF release rate of 125 6 12 pg/24 hour/106 cells
(Figure 2B). BDNF-expressing cells had a neuronal-
like shape anddid not express nestin after 3 days, in con-
trast to the fibroblast-like morphology of nestin1 cellshMSC cultures and increases the percentage of nestin-positive cells. (A)
ercentage of nestin1 cells was maintained in media supplemented with
hth (8) day. (B) Effect of different media on the generation of BDNF-
tained from conditioned medium (**P\ .01, n 5 3, Student’s t-test).
d) and anti-BDNF (green, C) or anti-phospho-TrkB (green, D) of hMSC
dium [hM(N)SC]. There were two different subpopulations of cells, as
stained with DAPI (C, blue). Scale bar: 20 mm.
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phorylated in nestin-negative cells (Figure 2D). Alto-
gether, these data indicated that the application of
NSC1GF-medium for 3 days constitutes an appropri-
ate neural induction protocol to generate hMSC cul-
tures with an increased nestin1-subpopulation and
BDNF-secreting cells with activated TrkB receptors.
We therefore named the hMSC cultured with this
medium hM(N)SC.Effect of Grafted hM(N)SC into the Intact SN
Based on the above data, we generated hM(N)SC
by applying the neural induction protocol to hMSC
cultures to transplant them into the SN for in vivo
characterization (Figure 3A). Before examining
whether hM(N)SC might release BDNF in vivo in
the SN and exert a neurotrophic effect on dopaminer-
gic neurons, we evaluated basic transplantation param-
eters like cell survival and engraftment. We detected
surviving human cells throughout the ventral right
SNpc after immunostaining for human ribonucleo-
protein [40] (hRNP, Figure 3B). The hM(N)SC grafts
did not disrupt the normal cytoarchitecture of the
brain; there was no sign of cell overgrowth or tumor
formation at the level of SN in any of the experimental
animals (Figure 3C), and a discrete lateral migration,
0.5-1 mm away from the injection site, was observed
(Figure 3B). The number of TH1 cells did not change
for any grafted animals (Figure 3D). We observedFigure 3. Nondisruptive integration of hM(N)SC cell transplantswithout delet
onal view of fresh brain following injection at the level of SN (see coordinates i
tation sites at the level of the intermedia (i) region. Within the boxed areas:
respectively. (B) Immunolabeling with anti-hRNP (black) showed the survival
mm. (C) Representative TH-immunostaining of a brain section at the level of the
(left) and grafted (right) hemispheres of the SNpc 1 week postgrafting. Scale bimmunolabeling of phosphorylated-Trk receptors
around the implant site that colocalized partially
with TrkB (right, Figure 4A). Additionally, we
observed a trend of an increased area of TH1 cells,
which was significant for the intermedia SNpc region
of 1 animal (Figure 4B). We also found occasional do-
nor human cells expressing TH at the implant site
(Figure 4C). In summary, we observed that hM(N)SC
grafted well into the SN after 1 week and had a neuro-
trophic effect on the intact SNpc.Effect of Grafted hM(N)SC into the Lesioned SN
At this point, we asked whether intranigral trans-
plantation of hM(N)SC could exert an effective neuro-
trophic support onnigrostriatal dopaminergic pathway.
We injected either vehicle (n5 6) or cells (2 105 cells,
n 5 7) into the partially lesioned SNpc at 1 week
postinjection with 6-OHDA and evaluated the effects
after 3 weeks, according to the experimental design
(Figure S1). Similar to the observations shown earlier
for transplantation into the intact SN, we detected
human cells (Figure 5B) and immunolabeling for
TrkB and phosphorylated-Trk receptors after trans-
plantation into the lesioned SN (Figure 5C). However,
we did not find human cells expressing TH (data not
shown). Although both hemispheres showed a similar
number of nigral TH1 cells per section (intact side:
hM(N)SC, 252 6 53, vehicle, 225 6 33; lesioned side:
hM(N)SC, 1016 172, vehicle, 1056 31), the sproutingerious effect on SNpc dopaminergic neurons. (A) The image shows a cor-
n Methods) to examine the implant location. Circles indicate the implan-
m, i, and l, indicate medial, intermedia, and lateral region of the SNpc,
and moderate migration of human cells in the rat SN. Scale bar: 200
cell transplant and (D) quantification of total TH1 cells in the nongrafted
ar: 1 mm.
Figure 4. In vivo effect of BDNF-secreting hMSCs into the intact SNpc 1 week postgrafting. (A) Images obtained by confocal microscopy after double
immunolabeling with anti-phospho-Trk (green) and anti-TrkB (red) antibodies in the left and right hemisphere of a grafted rat brain. Colocalization of
fluorescence (yellow) indicates highly probable activation of TrkB receptors on the right (transplanted) side. Scale bar: 500 mm. (B) Soma area was
calculated for a total of 100-400 TH1 cells for each SNpc region (m, medial; i, intermedia; l, lateral; )P\.05). (C) Representative composition from
serial confocal images at the level of the implant site shows some grafted cells expressing the dopaminergic maker TH. The top arrow indicates a human
cell (red, nuclear label), whereas the inferior arrow indicates an endogenous dopaminergic cell (green, cytoplasmic label). The arrowhead indicates
a human TH-expressing cell (red nucleus, green cytoplasm). Scale bar: 100 mm.
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nigrostriatal neurons, was increased in the right Str of
lesioned-grafted rats after 3 weeks compared to the
sham group (Figure 5D). Additionally, we measured
the soma area of nigral TH1 cells from SNpc and we
found greater values in the right side of lesioned-
grafted rats (Figure 5E). In terms of behavior, the
number of amphetamine-induced rotations increased
significantly after 3 weeks only in the lesioned-sham
group with respect to pregrafting data (126.7% of
average increase), but not in the lesioned-grafted rats
(Figure 5F), suggesting that neurodegeneration pro-
gressed more in nongrafted rats. Altogether, these
data suggested that hM(N)SC could be exerting a spe-
cific neurotrophic effect on the dopaminergic neurons
of the lesioned SNpc.DISCUSSION
Thefirst relevant finding of the present study is that
hMSC are effectively induced to express and releaseBDNF after being cultured in the serum-free medium,
NSC1GF, and that this effect seems to be restricted to
the nestin-negative subpopulation. The signals in-
volved in BDNF induction include the absence of
FBS and the presence of EGF and bFGF. Second, it
is the first time that hMSC-derived cells implanted
into the SN survived and integrated well into the host
to form a chimeric tissue. Human cells remained close
to the implant site and did not disrupt the SNpc archi-
tecture.We also observed signs of neuronal transdiffer-
entiation in some human cells implanted into the
intact, but not lesioned, SN that expressed the dopami-
nergic marker TH, although the total number of TH1
cells remained unchanged. Additionally, we observed
hypertrophy of nigral cells and graft-dependent activa-
tion of TrkB and other Trk receptors at the implant
site, suggesting that grafted hM(N)SC could deliver
bioactive BDNF into both the intact and lesioned
SN. The third important finding is that intranigral
cell grafts did not alter the number of dopaminergic
cells in the SNpc but exerted a neurotrophic support
Figure 5. Effect of hM(N)SC on the lesioned nigrostriatal pathway. (A) Representative sections show TH staining of Str and SNpc after 4 weeks of
6-OHDA striatal injection and 3 weeks after intranigral cell transplantation into the right hemisphere. (B) Specific human anti-hRNP antibody revealed
grafted cells at different places around the implant site (white arrows) in the right SNpc of a lesioned-grafted rat. The circles indicate the 2 injection
sites. Scale bar, 250 mm. High magnification of boxed area shows cells (brown) perfectly integrated into the brain tissue 3 weeks postimplantation. Scale
bar, 100 mm. (C) Representative confocal image obtained from the right SNpc of a lesioned-grafted rat shows TrkB (red), phosphorylated Trk receptors
(green), or phosphorylated TrkB, resulting from merging of red and green fluorescence (yellow) at the implant site. Scale bar, 250 mm. (D) Graphic
represents the sprouting index calculated from TH staining data. For the lesioned-grafted group, a significant difference were found between the intact
(L, left) and lesioned (R, right) side and with respect to the lesioned-sham group (#P\ .05). (E) Hypertrophy of TH1 cells was induced in the right
SNpc of the grafted rats (black bars) with respect to the sham rats (white bars) (#P\ .05). (F) The number of amphetamine-induced rotations was
compared with the baseline measurement of each rat (pregrafting condition: 1 week postlesion). Three weeks postgrafting the number of AIRs
increased (*P\.05) for the lesioned-sham group (white bars) but not for the lesioned-grafted group (black bars).
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minergic system as suggested by the hypertrophy of
nigral somas and the increased innervated area in the
striatum.
The ability of undifferentiated hMSC to express
neurotrophic factors in FBS-containing medium is
controversial. Here, we were able to induce BDNF re-
lease by hMSC cultures when cultured in NSC1GF,
at levels 3- to 10-fold higher than in other studies using
serum-containing medium [10,11]. In agreement with
this, we detected nestin-negative cells with low BDNFlevels when we used medium containing 10% FBS
(Figure S2). This was undetectable by our ELISA assay
(with a sensitivity limit of 7.8 pg/mL).
The mechanisms that modulate BDNF release in
hMSCarenot fully understood. In addition, hMSCcul-
tures are composed of heterogeneous populations of
mesenchymal progenitors with different commitments,
as described before in clonal studies [34,46]. Our
hMSC cultures grown in serum-free media (NSC or
NSC 1 GF) had downregulated levels of early neural
and mesenchymal markers (nestin and/or ASMA,
1538 Biol Blood Marrow Transplant 16:1530-1540, 2010R. Somoza et al.respectively) and expressed glial and neuronal markers
(Table 1). Moreover, the subpopulation of BDNF1
cells were grouped, had a neuronal-like morphology,
and were nestin-negative. This could indicate a more
mature neural state of cells, aswas found in adult human
olfactory neural progenitors after the addition of N2
and B27 supplements to a serum-free medium [47].
Moreover, BDNF is upregulated under adverse condi-
tions such as serum deprivation in neuronal cultures
[48]. Therefore, we postulate that in the nestin-
negative subpopulation, reflecting cells more commit-
ted toward a neuronal fate, serum deprivation in the
presence of EGF and bFGF leads to phosphorylation
of the transcription factor CREB and subsequently to
BDNF transcription, synthesis, and release as reported
for cells of neural origin [48-50].
Nestin is a marker of an undifferentiated neural
state and is expressed in human neural progenitor cells
(hNPC) [51]. It is now accepted that immature hMSC
from adult bone marrow usually express nestin as well
[34,52-54]. Therefore, EGF and bFGF, which were
present in our induction medium, could be acting as
survival factors in uncommitted nestin1 cells, as it has
been shown in hNPC cultures [51]. However, BDNF
secreted by nestin-negative cells would have the oppo-
site effect on nestin expression [55], as suggested previ-
ously in a clonal study [34]. This could be mediated by
TrkB activation that occurs exclusively in nestin-
negative cells as we observed after applying our neural
induction protocol, but not a standard culture medium
(see Figure S2). Moreover, BDNF added to defined
differentiation medium results in dopaminergic differ-
entiation of hMSC [56]. Therefore, BDNF secreted
by hMSC-derived nestin-negative cells could induce
neuronal self-differentiation.
BDNF could synergize with other neurotrophins
that act through the Trk receptor family [57,58].
NGF is the ligand for TrkA, whereas BDNF and
NT-4/5 bind to TrkB, and NT-3 binds to TrkC.
BDNF and NT-3, but not NGF, have roles in the sur-
vival and function of dopaminergic neurons [59].
BDNF also can induce hypertrophy of dopaminergic
cells [60]. The hypertrophic effect of grafted hM(N)SC
on dopaminergic neurons together with the detection
of phospho-Trk receptors at the implant site both in
the intact and lesioned SNpc sugests a BDNF-
mediated effect. Additionally, we coimmunodetected
TrkB in 97%-100% nigral TH1 cells. However, we
cannot exclude the possibility that other neurotrophic
factors, such as GDNF, were released by our cells
and affected nigral dopaminergic cells. Indeed, another
study described hypertrophy or sprouting of nigral do-
paminergic cells when implanting GDNF-secreting
fibroblasts in the dorsal SNpc [61]. Furthermore, we
found that striatal TH-staining area was higher in
lesioned-graftedwith respect to lesioned-sham animals
at 4 weeks postlesion. This result, together with Trkactivation at the implantation site and hypertrophy of
nigral TH1 cells, suggest that cells release neurotro-
phins (eg, BDNF) in vivo that exert a positive action
on the degenerating nigrostriatal dopaminergic path-
way. Although it has been published recently that intra-
striatal administration of 6-OHDA produced an early
and transient augmentation of BDNF expression at 1
week [62], we did not find TrkB activation in non-
grafted SNpc at 4 weeks postlesion (data not shown).
However, the enhancement of striatal sprouting and
soma area in the lesioned side of grafted animals sug-
gests that BDNF, among other neurotrophic factors,
could be directly promote the survival, hypertrophy,
and sprouting of dopaminergic neurons or even facili-
tate the release of DA from host DA neurons as previ-
ously reported [63]. As the injection of 6-OHDA in
the Str produces a progressive model of PD that needs
about 3 to 4weeks to complete the process [64], our his-
tologic data suggest that the hM(N)SC might protect
or rescue impaired dopaminergic neurons in the
SNpc, thereby improving motor deficits.
Ourednik and collaborators [65] showed that intra-
nigral grafts of themouseNSC lineC17.2 can promote
sprouting of spared nigrostriatal dopaminergic effer-
ents and induce functional recovery of the dopaminer-
gic neurons after transplantation into the partially
lesioned SN, an effect that might probably mediated
byGDNF.However, they did not showGDNF recep-
tor activation in the host tissue. Previously, we de-
scribed that C17.2 cells could release 55 pg/24 hour/
106 cells of BDNF in the absence of any genetic mod-
ification [66]. Therefore, the functional effects in PD
models observed using this cell line [65] could also be
mediated by BDNF/TrkB signaling.
With respect to a possible therapeutic effect, the
stabilization of rotations observed in the grafted rats be-
tween pregrafting and 3 weeks postgrafting is in
accordance with higher TH immunostaining in Str of
grafted versus sham animals. Thus, we postulate that
grafted cells were able to halt/slow down the nigrostria-
tal dopaminergic degeneration. As we did not find TH
expression in the grafted human cells detected in the
lesioned SNpc, the effect of grafted hM(N)SC in the
lesioned SN might not be because of cell replacement
of dopaminergic neurons, but a homeostatic effect on
the partially impaired nigrostriatal dopaminergic
system. We postulate that trophic factors released by
hM(N)SC stimulate an endogenous neuroprotective
response in the lesioned SN. However, we cannot
exclude other potential mechanisms, such as anti-
inflammatory, antioxidant, and/or immunoregulatory
actions [9,11,17,20,67].
In conclusion, the serum-free medium supple-
mented with EGF and bFGF used in this study leads
to BDNF expression and delivery. Our protocol is sim-
ple and reproducible, and could thus be used in future
cell therapies for several human neurodegenerative
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for Substantia Nigra Transplantationdisorders. In addition, the efficient intranigral
engraftment of these epigenetically induced BDNF-
secreting hMSC and the neurotrophic evidence
observed after transplantation into the ongoing degen-
erated nigrostriatal dopaminergic system suggest that
hM(N)SChold the promise of being able to supply bio-
activemolecules beneficial for survival andmaintenance
of impaired dopaminergic neurons in PD. In this way,
future therapies for several human BDNF-related neu-
rodegenerative disorders could be approached using
hMSC transplantation, taking advantage of their capac-
ity for neurotrophic factor delivery.ACKNOWLEDGMENTS
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